149 / 172
149
52. Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der
Heijde D. Favorable effect of very early disease-modifying
antirheumatic drug treatment on radiographic progression in
early inflammatory arthritis: Data from the Étude et Suivi des
polyarthrites indifférenciées récentes (study and followup of
early undifferentiated polyarthritis). Arthritis Rheum
2011;63:1804-11.
53. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M,
Rozman B, Williams D, et al, for the European Leflunomide
Study Group. Improved functional ability in patients with
rheumatoid arthritis: longterm treatment with leflunomide
versus sulfasalazine J Rheumatol 2001;28:1983-91.
54. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK,
Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model
for the prediction of rapid radiographic progression in patients
with rheumatoid arthritis receiving different dynamic
treatment strategies: post hoc analyses from the BeSt study.
Ann Rheum Dis 2010;69:1333-7.
55. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH.
Comparison of the efficacy of the tumour necrosis factor
alphablocking agents adalimumab, etanercept, and infliximab
when added to methotrexate in patients with active
rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl2):ii13-6.
56. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A,
Hansen IT, et al. Direct comparison of treatment responses,
remission rates, and drug adherence in patients with
rheumatoid arthritis treated with adalimumab, etanercept, or
infliximab: results from eight years of surveillance of clinical
practice in the nationwide Danish DANBIO registry. Arthritis
Rheum 2010;62:22-32.
57. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de
Vries-Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical
and radiological efficacy of initial vs delayed treatment with